Bausch + Lomb Corporation (NYSE and TSX: BLCO), a global eye health company, was at last look down 7% in US premarket trade on Thursday after it issued an update on a potential sale, which was disclosed in December 2024 following a regulatory request.
"Taking Bausch + Lomb private with a third-party buyer was one of several options being explored to complete a full separation from Bausch Health Companies Inc. After engagement with potential buyers, that process is complete, and will not result in a transaction at this time," Thursday's statement said.
"Full separation remains the goal. Bausch + Lomb continues to operate as its own entity and execute on its strategies and business plan.
The company, which raised 2024 revenue guidance on October 30, will report fourth-quarter and full-year 2024 earnings on February 19, in addition to providing guidance for the 2025 fiscal year.
Bausch + Lomb is traded on both the New York Stock Exchange and Toronto Stock Exchange.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.